^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial
Published date:
09/10/2020
Excerpt:
...within the trastuzumab arm, a higher continuous pretreatment serum PD‐L1 level was significant for shorter OS (hazard ratio [HR], 3.85; P = .04)...
DOI:
10.1002/cncr.33149
